Prograf, Tacrolimus
Prograf, Tacrolimus Newswire

Prograf, Tacrolimus Newswire

Comprehensive Real-Time News Feed for Prograf, Tacrolimus (generic).

Results 1 - 15 of 15 in Prograf, Tacrolimus (generic)

  1. Veloxis Pharmaceuticals A/S Announces Financial Results For The First ...Read the original story

    Wednesday Aug 26 | BioSpace

    Veloxis Pharmaceuticals A/S Announces Financial Results For The First Six Months Of 2015 And Improves The Full Year Outlook EnvarsusA XR was granted Orphan Drug status by the U.S. Food and Drug Administration for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Veloxis has received U.S. Food and Drug Administration approval of EnvarsusA XR for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily EnvarsusA XR.

    Comment?

  2. FDA News Roundup: Otsuka, AstraZeneca, Ipsen, And MoreRead the original story w/Photo

    Jul 17, 2015 | Pharmaceutical Online

    Otsuka and Lundbeck's drug Rexulti received approval for adults with major depressive disorder and for adults with schizophrenia. The treatment was investigated in Phase 2 and 3 trials enrolling more than 4,300 patients.

    Comment?

  3. Extended-Release Tacrolimus (Envarsus XR) Wins FDA Nod for Kidney Transplant PatientsRead the original story

    Jul 13, 2015 | P&T Community

    The FDA has said "okay" to tacrolimus extended-release tablets for the prophylaxis of organ rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. Veloxis expects the drug to be available to physicians in the U.S. in the fourth quarter of 2015.

    Comment?

  4. Extended-Release Tacrolimus (Envarsus XR) Wins FDA Nod for Kidney Transplant PatientsRead the original story

    Jul 13, 2015 | P&T Community

    The FDA has said "okay" to tacrolimus extended-release tablets for the prophylaxis of organ rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. Veloxis expects the drug to be available to physicians in the U.S. in the fourth quarter of 2015.

    Comment?

  5. Envarsus XR receives FDA approval for treatment of kidney transplant recipientsRead the original story w/Photo

    Jul 11, 2015 | Medical News

    Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR. Veloxis expects Envarsus XR to be available to patients in the United States and their physicians in 4Q2015.

    Comment?

  6. EnvarsusA XR Demonstrates Differentiated Pharmacokinetic Profile...Read the original story

    Jun 24, 2015 | Freshnews

    Veloxis Pharmaceuticals A/S today announced top-line results of the ASTCOFF study, A ST eady-state Pharmacokinetic CO mparison Of all F K-506 F ormulations, demonstrating that once-daily Envarsus XR , an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics when compared to twice-daily tacrolimus ) or a once-daily tacrolimus product ).

    Comment?

  7. Veloxis Pharmaceuticals A/S Release: Envarsus XR Demonstrates...Read the original story

    Jun 23, 2015 | BioSpace

    Veloxis Pharmaceuticals A/S Release: Envarsus XR Demonstrates Differentiated Pharmacokinetic Profile Compared To Twice-Daily Prograf Or Once-Daily Astagraf XL In Stable Kidney Transplant Patients /PRNewswire/ -- Veloxis Pharmaceuticals A/S today announced top-line results of the ASTCOFF study, A ST eady-state Pharmacokinetic CO mparison Of all F K-506 F ormulations, demonstrating that once-daily EnvarsusA XR , an investigational new drug under FDA review for the prevention of organ rejection in adult kidney transplant patients, achieved differentiated pharmacokinetics when compared to twice-daily tacrolimus or a once-daily tacrolimus product .

    Comment?

  8. Astellas Pharma US, Inc. - Pharmaceuticals & Healthcare - Deals and...Read the original story

    May 12, 2015 | PR-inside.com

    The company manufactures and distributes pharmaceutical products. Its products include adenosine injection, regadenoson injection, tacrolimus ointment, tacrolimus capsules and injection, tacrolimus extended-release capsules, liposome for injection, micafungin sodium for injection, enzalutamide capsules and solifenacin succinate tablets.

    Comment?

  9. Generic Transplant Drugs Are Fine, But Patients Still WorryRead the original story

    May 10, 2015 | Scientific Blogging

    Generic drugs are the same as a name brand. The only difference is that a generic company does not research or clinical trials and since the product is outside patent, they only have the cost of manufacturing, so costs are lower and the product is cheaper.

    Comment?

  10. Study: Generic transplant drugs as good as brand nameRead the original story

    May 5, 2015 | Medical News Today

    A University of Cincinnati -led research team has found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version. The findings were presented by lead investigator Rita Alloway, PharmD, UC research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, and her study collaborators at the 2015 American Transplant Congress annual meeting in Philadelphia.

    Comment?

  11. Veloxis Pharmaceuticals A/S Release: Envarsus XR Demonstrates...Read the original story

    May 3, 2015 | BioSpace

    These data, which are from one of the largest trials of tacrolimus pharmacokinetics in African-American kidney transplant patients conducted to date, were presented at the American Transplant Congress on , in a presentation entitled "PK and Pharmacogenomics of Once-daily MeltDose Tacrolimus vs. Twice-daily Tacrolimus: A Randomized Cross-over Study in Stable African-American Kidney Transplant Patients ". There are several additional presentations on Envarsus XR at ATC, which are listed below.

    Comment?

  12. Generic transplant drugs as good as brand nameRead the original story w/Photo

    May 3, 2015 | Science Blog

    A University of Cincinnati -led research team has found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version. The findings were presented Sunday, May 3, by lead investigator Rita Alloway, PharmD, UC research professor of medicine and director of transplant clinical research within the UC Department of Internal Medicine, and her study collaborators at the 2015 American Transplant Congress annual meeting in Philadelphia.

    Comment?

  13. Generic transplant drugs as good as brand name, study findsRead the original story w/Photo

    May 3, 2015 | PhysOrg Weblog

    Rita Alloway, PharmD, director of transplant clinical research within the University of Cincinnati Department of Internal Medicine, with Sander Vinks, PharmD, UC professor of pediatrics and director of the Division of Clinical Pharmacology at Cincinnati Children's Hospital Medical Center. Credit: University of Cincinnati A University of Cincinnati -led research team has found that generic formulations of tacrolimus, a drug used post-transplant to lower the risk of organ rejection, are just as good as the name-brand version.

    Comment?

  14. Astellas Pharma US, Inc. - Strategic SWOT Analysis Review: New...Read the original story

    Mar 28, 2015 | PR-inside.com

    The company manufactures and distributes pharmaceutical products. Its products include adenosine injection, regadenoson injection, tacrolimus ointment, tacrolimus capsules and injection, tacrolimus extended-release capsules, liposome for injection, micafungin sodium for injection, enzalutamide capsules and solifenacin succinate tablets.

    Comment?

  15. Astellas Settles Lawsuits Alleging Prograf Generics DelayRead the original story

    Jan 20, 2015 | Bloomberg

    Astellas Pharma Inc. agreed to settle lawsuits over an alleged scheme to delay generic versions of its immune-suppressant drug Prograf, avoiding a trial set to start today. Drug wholesaler plaintiffs and the Tokyo-based company announced the agreement in principle today during a telephone conference, according to a filing in Boston federal court.

    Comment?